Teduglutide
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Teduglutide is listed as gut / glp-2 analog.
- •Short bowel syndrome
- •Intestinal mucosal growth research
Regulatory status: FDA-Approved Rx.
Structure & Properties
Compound: Teduglutide; also known as Gattex, Revestive.
Pharmacologic class: Gut / GLP-2 Analog.
Known delivery routes: Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
DPP-4-resistant GLP-2 analog that increases intestinal villus height, crypt depth, and nutrient absorption.
- •Reduced parenteral nutrition dependence
- •Improved intestinal absorptive surface
Human Research
Evidence grade: Clinical RCT (Phase III)
Clinical RCT (Phase III). Phase III STEPS program.
Laboratory Research
Phase III STEPS program
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
No strict time-of-day requirement. Dose consistently at the same time daily and rotate injection sites. Follow the per-peptide dosing section above.
Potential interactions and combinations to avoid
- •Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- •Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Colorectal polyp/neoplasia risk — colonoscopy surveillance required
- •Abdominal pain and distension
- •Fluid overload
- •Biliary and pancreatic disease
Contraindications
- •Active GI malignancy
- •Unscreened colon
- •Pregnancy (limited data)
- •Hypercalcemia, hyperparathyroidism, or Paget's disease of bone
- •History of skeletal radiation therapy or osteosarcoma
- •Unexplained elevated alkaline phosphatase or bone metastases
- •Myocardial infarction or stroke within the previous 12 months (sclerostin inhibitors)
- •Severe renal impairment or active kidney stone disease
- •Active gastrointestinal malignancy, polyposis, or undiagnosed GI bleeding
- •Colorectal adenoma history without current colonoscopic surveillance
- •Bowel obstruction, stricture, or acute abdominal pain of unknown cause
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 0.05 mg/kg/day
Frequency: Daily
Cycling: Continuous daily therapy with periodic colonoscopy.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is Teduglutide?
In plain words
Teduglutide is a prescription medicine that mimics a natural gut hormone. The body breaks it down less easily, allowing it to help the gut lining grow and absorb more nutrients. It has been studied in major clinical trials for short bowel syndrome and is FDA-approved for that condition. A key safety concern is abnormal growths in the colon, including potentially cancerous growths, so colonoscopy monitoring is required.
Technical definition
Teduglutide (Gattex, Revestive) is a peptide analog of glucagon-like peptide-2 (GLP-2) that resists degradation by dipeptidyl peptidase-4 (DPP-4). It acts at the GLP-2 receptor to increase intestinal villus height, crypt depth, and nutrient absorption. It is FDA-approved as a prescription treatment for short bowel syndrome, with evidence from Phase III randomized controlled trials.
Function
Dosing
Recommended Time of Day
Once daily, same time each day — any time.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous daily therapy with periodic colonoscopy.
Timing & Interactions
- ·Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- ·Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
- ·Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Teduglutide and sync them to Vial Lab.
Benefits
- ·Reduced parenteral nutrition dependence
- ·Improved intestinal absorptive surface
Risks
- ·Colorectal polyp/neoplasia risk — colonoscopy surveillance required
- ·Abdominal pain and distension
- ·Fluid overload
- ·Biliary and pancreatic disease
Contraindications
- ·Active GI malignancy
- ·Unscreened colon
- ·Pregnancy (limited data)
- ·Hypercalcemia, hyperparathyroidism, or Paget's disease of bone
- ·History of skeletal radiation therapy or osteosarcoma
- ·Unexplained elevated alkaline phosphatase or bone metastases
- ·Myocardial infarction or stroke within the previous 12 months (sclerostin inhibitors)
- ·Severe renal impairment or active kidney stone disease
- ·Active gastrointestinal malignancy, polyposis, or undiagnosed GI bleeding
- ·Colorectal adenoma history without current colonoscopic surveillance
- ·Bowel obstruction, stricture, or acute abdominal pain of unknown cause
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved Rx
Veterinary Use (Pets)
No established veterinary protocol for Teduglutide. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.